Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF V600E Co-mutations predict aggressive clinicopathological features in Chinese patients with differentiated thyroid cancer: A multicenter cohort study.

Cancer treatment and research communications - 1 Jan 2026

Du Jing, Guo Bo, Zhang Yunpeng, Guo Songyan, Yang Fan

Abstract excerpt

BACKGROUND: The BRAF V600E mutation is a common driver variant in differentiated thyroid carcinoma (DTC); however, the clinical significance of its co-mutation patterns in the Chinese population remains unclear. This study aimed to analyze the predictive value of BRAF V600E co-mutations for aggressive clinicopathological features in DTC by detecting a 10-gene panel, providing molecular evidence for refined risk...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to China

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to East Asian People

Share to NTRK3 gene

Share to Mutation

Share to Prognosis

Share to Proto-Oncogene Proteins B-raf

Share to Thyroid Neoplasms

Source

Identifiers

PMID: 42556006
DOI: 10.1016/j.ctarc.2026.101356

Genes

BRAF
TERT
HRAS
KRAS
NRAS
NTRK1
NTRK3
PIK3CA
PPARG
RET

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF V600E Co-mutations predict aggressive clinicopathological features in Chinese patients with differentiated thyroid cancer: A multicenter cohort study.PMID 42556006Read ↗

BRAF V600E mutation co-existing with oncogenic mutations is associated with aggressive clinicopathologic features and poor prognosis in papillary thyroid carcinoma.Semantic proximity Read ↗

Multi-gene co-mutations of BRAF with TERT, PIK3CA, or TP53 are powerful predictors of central lymph node metastasis in papillary thyroid carcinoma.Semantic proximity Read ↗

Genetic analysis and clinicopathologic features of locally advanced papillary thyroid cancers: a prospective observational study.Semantic proximity Read ↗

Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest ChinaSemantic proximity Read ↗

Preoperative Co-Mutation of BRAFV600E and TERT Promoter Predicts Tumor Aggressiveness and Recurrence-Free Survival in Papillary Thyroid Carcinoma.Semantic proximity Read ↗

Comprehensive genomic profiling from C-CAT database unveiled over 80% presence of oncogenic drivers in anaplastic thyroid carcinoma including BRAF, RAS family, NF1, and FGFR1.Semantic proximity Read ↗

High Concordance in Molecular Profiles Between Primary Tumors and Matched Lymph Node Metastases in Differentiated Thyroid Carcinoma: Implications for Clinical Sample SelectionSemantic proximity Read ↗

Effects of Coexistent BRAFV600E and TERT Promoter Mutations on Poor Clinical Outcomes in Papillary Thyroid Cancer: A Meta-Analysis.Semantic proximity Read ↗

Identification of RET fusions in a Chinese multicancer retrospective analysis by next‐generation sequencingSemantic proximity Read ↗

Evaluation of BRAF V600E and TERT mutation analysis in differential thyroid cancers.Semantic proximity Read ↗

Molecular Profile of Locally Aggressive Well Differentiated Thyroid Cancers.Semantic proximity Read ↗

The mutation profile of differentiated thyroid cancer coexisting with undifferentiated anaplastic cancer resembles that of anaplastic thyroid cancer but not that of archetypal differentiated thyroid cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.